Home › Research › Cognitive tests and assessment
Digital Biomarkers Based Individualized Prognosis for People at Risk of Dementia: the AltoidaML Multi-site External Validation Study
Laura Rai, Rory Boyle, Laura Brosnan, Hannah Rice, Francesca Farina, Ioannis Tarnanas, Robert Whelan. Advances in experimental medicine and biology, 2020
Topic: Brain imaging, connectivity and assessment
Research investigating treatments and interventions for cognitive decline and Alzheimer's disease (AD) suffer due to difficulties in accurately identifying individuals at risk of AD in the pre-symptomatic stages of the disease. There is an urgent need for better identification of such individuals in order to enable earlier treatment and to properly stage and stratify participants for clinical trials and intervention studies. Although some biological measures (biomarkers) can identify Alzheimer's-related changes before significant changes in cognitive function occur, such biomarkers are not ideal as they are only able to place individuals in rudimentary stages of the disease/cognitive decline (Tarnanas et al., Alzheimers Dement (Amst) 1(4):521-532, 2015) and sometimes mistakenly diagnose individuals (Edmonds et al. 2015). Two tests, based on real-world functioning, which have been used to screen for pre-symptomatic AD are (i) dual-task walking tests (Belghali et al. 2017) and (ii) day-out tasks (Tarnanas et al. 2013). A novel digital biomarker, the Altoida ADPS app, which implements gamified versions of these tests has been shown to accurately discriminate between healthy controls and individuals in prodromal stages of Alzheimer's disease (Tarnanas et al. 2013) and can differentiate between people with mild cognitive impairment who convert to Alzheimer's disease and those who don't (Tarnanas et al. 2015b). The aim of this study is the validation of a novel digital biomarker of cognitive decline.
Key findings
- Although some biological measures (biomarkers) can identify Alzheimer's-related changes before significant changes in cognitive function occur, such biomarkers are not ideal as they are only able to place individuals in rudimentary stages of the disease/cognitive decline (Tarnanas et al., Alzheimers Dement (Amst) 1(4):521-532, 2015) and sometimes mistakenly diagnose individuals (Edmonds et al. 2015).
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 22 of the 56 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Advances in experimental medicine and biology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32468532) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 22 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 22 of the 56 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Rai, L., Boyle, R., Brosnan, L., Rice, H., Farina, F., Tarnanas, I., et al. (2020). Digital Biomarkers Based Individualized Prognosis for People at Risk of Dementia: the AltoidaML Multi-site External Validation Study. Advances in experimental medicine and biology. https://doi.org/10.1007/978-3-030-32622-7_14
Vancouver
Rai L, Boyle R, Brosnan L, Rice H, Farina F, Tarnanas I, et al. Digital Biomarkers Based Individualized Prognosis for People at Risk of Dementia: the AltoidaML Multi-site External Validation Study. Advances in experimental medicine and biology. 2020. doi:10.1007/978-3-030-32622-7_14. PMID: 32468532.
BibTeX
@article{rai2020-32468532,
author = {Rai, Laura and Boyle, Rory and Brosnan, Laura and Rice, Hannah and Farina, Francesca and Tarnanas, Ioannis and Whelan, Robert},
title = {{Digital Biomarkers Based Individualized Prognosis for People at Risk of Dementia: the AltoidaML Multi-site External Validation Study}},
journal = {Advances in experimental medicine and biology},
year = {2020},
doi = {10.1007/978-3-030-32622-7_14},
pmid = {32468532},
url = {https://doi.org/10.1007/978-3-030-32622-7_14}
}
Related studies in Cognitive tests and assessment
Also tagged “computerized”
238 studies in the library carry the topic tag “computerized”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 238 tagged studies.